Adaptive Biotechnologies Corp vs NEOS S&P 500 High Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while NEOS S&P 500 High Income ETF trades at $54.15. Which is the better fit depends on your goals.
| ADPT | SPYI | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $25.45 | $54.19 |
52-Week Low | $12.30 | $47.98 |
Enterprise Value | $4.10B | — |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →